While traditional antibodies are limited to cell-surface antigens, our next-generation TCR-mimic (TCRm) antibody platform enables targeting of the vast intracellular proteome, allowing us to address tumour-specific targets such as cancer-testis antigens. This presentation will detail engineering strategies to build next-generation TCRm T cell engagers, designed to achieve a greater therapeutic window in targeting HLA-peptide complexes, and share recent data on how to overcome challenges in treatment of solid tumours.

Single domain antibodies (sdAbs) are versatile building blocks for the design of of bi- and multifunctional- antibody architectures. In this talk, I will present strategies to engineer sdAb-based antibodies that selectively agonise cytokine receptors. I will give examples on several different bi- and multi-specifics that ‘mimic’ the function of given cytokines in the tumour, as well as autoimmune context, and will provide mechanistic insights for the generation of such entities.

Humoral immunity is increasingly recognised as a key determinant of outcome in melanoma. This talk will focus on distinct circulating and intratumoural B cell signatures and antibody isotype profiles we found to be be linked with response and toxicity associated with immune checkpoint inhibitor immunotherapy. Humoral immune signatures conditioned in tumour environments, reveal novel biomarkers for predicting and monitoring immunotherapy efficacy.